Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 3, 2013, Pages 217-223

  Santovito, Donato ^a   Mandolini, Claudia ^a   Marcantonio, Pamela ^a   De Nardis, Velia ^a   Bucci, Marco ^a   Paganelli, Camilla ^a   Magnacca, Francesco ^a   Ucchino, Sante ^a   Mastroiacovo, Daniela ^b   Desideri, Giovambattista ^c   Mezzetti, Andrea ^a   Cipollone, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SS Filippo e Nicola Hospital   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Atherosclerotic plaques; Hypertension; MicroRNA; MiR 145

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MICRORNA 145;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HYPERTENSION; MALE; UPREGULATION;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERTENSION; MALE; MICRORNAS; PLAQUE, ATHEROSCLEROTIC;

EID: 84873884092     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.745512     Document Type: Article

References (31)

1. World Health Organization. Global atlas on cardiovascular disease prevention and control. In: Mendis S, Puska P, Norrving B, editors. World health organization. World Health Organization, Geneva; 2011
2. Santovito D, Mezzetti A, Cipollone F. MicroRNAs and atherosclerosis: new actors for an old movie. Nutr Metab Cardiovasc Dis 2012;22(11):937-43
3. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009;16:1590-8
4. Boettger T, Beetz N, Kostin S, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009;119:2634-47
5. Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009;105:158-66
6. Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009;23:2166-78
7. Cipollone F, Felicioni L, Sarzani R, et al. A unique microrna signature associated with plaque instability in humans. Stroke 2011;42:2556-63
8. Raitoharju E, Lyytikainen L-P, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 2011;219:211-17
9. Bidzhekov K, Gan L, Denecke B, et al. microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans. Thromb Haemost 2012;107:619-25
10. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation 2011;124:e54-e130
11. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415-25
12. Witkos TM, Koscianska E, Krzyzosiak WJ. Practical Aspects of microRNA Target Prediction. Curr Mol Med 2011;11:93-109
13. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460:705-10
14. Caruso P, Dempsie Y, Stevens H, et al. A. role for miR-145 in pulmonary arterial hypertension. Circ Res 2012;111:290-300
15. Turczynska KM, Sadegh MK, Hellstrand P, et al. MicroRNAs are essential for stretch-induced vascular smooth muscle contractile differentiation via microRNA (miR)-145-dependent expression of L-type calcium channels. J Biol Chem 2012;287:19199-206
16. Moosmang S, Schulla V, Welling A, et al. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J 2003;22:6027-34
17. Wilde DW, Furspan PB, Szocik JF. Calcium current in smooth muscle cells from normotensive and genetically hypertensive rats. Hypertension 1994;24:739-46
18. Li H, Li W, Gupta AK, et al. Calmodulin kinase II is required for angiotensin II-mediated vascular smooth muscle hypertrophy. Am J Physiol Heart Circ Physiol 2010;298:H688-98
19. Flamant M, Placier S, Rodenas A, et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol 2006;17:3374-81
20. Yoshikawa A, Aizaki Y, Kusano K-I, et al. The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space. Hypertens Res 2011;34:599-605
21. Yu Y, Lucitt MB, Stubbe J, et al. Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis. Proc Natl Acad Sci USA 2009;106:7985-90
22. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204:321-9
23. Mogelvang R, Pedersen SH, Flyvbjerg A, et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012;109:515-20
24. Levula M, Oksala N, Airla N, et al. Genes involved in systemic and arterial bed dependent atherosclerosis-Tampere Vascular study. PLoS One 2012;7:e33787
25. Martinez J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002;110:563-74
26. van Rooij E. The art of microRNA research. Circ Res 2011;108:219-34
27. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011;478:404-7
28. Santaris Pharma A:S to report new clinical data from miravirsen Phase 2a study to treat Hepatitis C [Internet]. santaris.com. 2011. Available from: http://www.santaris.com/news/2011/10/03/santaris-pharma-report-new-clinical- data-miravirsen-phase-2a-study-treat-hepatitis-c [Cited 19 October 2012]
29. Thomas JA, Deaton RA, Hastings NE, et al. PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patterns. Am J Physiol Heart Circ Physiol 2009;296:H442-52
30. Parmacek MS. MicroRNA-modulated targeting of vascular smooth muscle cells. J Clin Invest 2009;119:2526-28
31. Suzuki T, Sawaki D, Aizawa K, et al. Kruppel-like Factor 5 Shows Proliferation-specific Roles in Vascular Remodeling, Direct Stimulation of Cell Growth, and Inhibition of Apoptosis. J Biol Chem 2009;284:9549-57